Skip to main content
 

Biosimilars Forum Applauds Food and Drug Administration on New Educational Program Promoting Safety and Effectiveness of Biosimilars

Washington, D.C. (October 24, 2017) – The Biosimilars Forum issued the following statement on the Food and Drug Administration (FDA)’s new educational program promoting the safe and effective use of biosimilars.

“The Biosimilars Forum is pleased that the Food and Drug Administration (FDA) has invested considerable time and resources into developing a comprehensive biosimilars education program. This program demonstrates the FDA’s commitment to educating patients, providers, and others about biosimilars as safe and effective treatment options for patients with serious diseases. The Biosimilars Forum is committed to working with FDA to continue its crucial work to educate all stakeholders about the importance of biosimilars for improving patients’ access to lifesaving treatment options.”

About the Biosimilars Forum

The Biosimilars Forum is a nonprofit organization whose mission is to advance biosimilars in the United States with the intent of expanding access and availability of biological medicines, and improving health care. The founding members of the Biosimilars Forum represent the majority of companies with the most significant U.S. biosimilars development portfolios.

To learn more about biosimilars, the Forum, and how to get involved, visit BiosimilarsForum.org, @USbiosimilars, or Facebook/USBiosimilars to follow related conversations and join the dialogue.

Contact:
Aimee Steel Lubin
202.828.1895
aimee.lubin@hklaw.com

Date

Tuesday, October 24, 2017 - 4:00pm